A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from birth
- Coverage possible with two-week gap before early delivery
- Vaccination during third trimester still offers meaningful protection for infants
Compelling evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been established through a thorough investigation carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing strong and reliable data of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation provides healthcare professionals and prospective parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This stark contrast underscores the vaccine’s critical role in protecting against serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Study design and parameters
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed actual clinical results rather than laboratory-based settings, providing real-world data of how the vaccine performs when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to breathe and feed properly. Parents often witness their babies visibly struggling, their chests heaving as they work to get enough air into their compromised lungs. Whilst most newborns improve through supportive care, a modest yet notable proportion perish from RSV-related complications annually, making prevention through vaccination a essential public health objective for safeguarding the youngest and most at-risk individuals in the population.
- RSV triggers inflammation in lungs, leading to severe breathing difficulties in babies
- Half of all infants catch the infection in their first few months of life
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Few babies succumb to RSV related complications each year in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that the timing is essential for ensuring newborns receive the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These regional differences reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to engage with pregnant women
- Geographic variations in vaccination coverage levels in different parts of England demand focused enhancement
- Local healthcare systems modifying schemes to suit specific population needs
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness provides real advantages for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this preventative solution, the 80% drop in admissions equates to thousands of infants protected against severe infection. Parents no more face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the terrain of neonatal breathing health, providing expectant mothers a active means to protect their youngest infants during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection resulted in profound brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s support of the jab emphasises the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to women in pregnancy navigating their late pregnancy, converting what was once an unavoidable seasonal threat into a manageable risk.